426 related articles for article (PubMed ID: 23697556)
1. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
Li C; Ji H; Cai Y; Ayana DA; Lv P; Liu M; Jiang Y
J Interferon Cytokine Res; 2013 Oct; 33(10):612-8. PubMed ID: 23697556
[TBL] [Abstract][Full Text] [Related]
2. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Ma L; Cai YJ; Yu L; Feng JY; Wang J; Li C; Niu JQ; Jiang YF
Antimicrob Agents Chemother; 2013 Mar; 57(3):1304-11. PubMed ID: 23274669
[TBL] [Abstract][Full Text] [Related]
3. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
4. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Yang X; Li J; Liu J; Gao M; Zhou L; Lu W
Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
[TBL] [Abstract][Full Text] [Related]
6. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B.
Wang HJ; Jiang YF; Wang XR; Zhang ML; Gao PJ
World J Gastroenterol; 2016 May; 22(18):4529-37. PubMed ID: 27182162
[TBL] [Abstract][Full Text] [Related]
8. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
Sulaiman A; Lesmana LA; Nafrialdi ; Helyanna
Acta Med Indones; 2014 Jan; 46(1):38-43. PubMed ID: 24760807
[TBL] [Abstract][Full Text] [Related]
9. Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B.
Li MH; Lu Y; Zhang L; Wang XY; Ran CP; Hao HX; Zhang D; Qu XJ; Shen G; Wu SL; Cao WH; Qi TL; Liu RY; Hu LP; Chang M; Hua WH; Liu SA; Wan G; Xie Y
Chin Med J (Engl); 2018 Aug; 131(15):1813-1818. PubMed ID: 30058578
[TBL] [Abstract][Full Text] [Related]
10. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su QM; Ye XG
World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
13. Positive association between serum apolipoprotein M levels and hepatitis B virus DNA load in HBeAg-negative chronic hepatitis B.
Shen T; Wu WM; Du WH; Wang L; He G; Tan L; Wang Z; Chen R; Hu M; Ren YP
Lipids Health Dis; 2016 Dec; 15(1):210. PubMed ID: 27927202
[TBL] [Abstract][Full Text] [Related]
14. Association of cytokines with hepatitis B virus and its antigen.
Li MH; Chen QQ; Zhang L; Lu HH; Sun FF; Zeng Z; Lu Y; Yi W; Xie Y
J Med Virol; 2020 Dec; 92(12):3426-3435. PubMed ID: 32662892
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.
Gan W; Li J; Zhang C; Chen X; Lin C; Gao Z
BMC Infect Dis; 2020 Dec; 20(1):931. PubMed ID: 33287722
[TBL] [Abstract][Full Text] [Related]
16. Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients.
Wang L; Qiu J; Yu L; Hu X; Zhao P; Jiang Y
J Transl Med; 2014 Sep; 12():251. PubMed ID: 25199644
[TBL] [Abstract][Full Text] [Related]
17. The serum interleukin-26 level is a potential biomarker for chronical hepatitis B.
Luo L; Jiang L; Tian Z; Zhang X
Medicine (Baltimore); 2020 Jan; 99(1):e18462. PubMed ID: 31895778
[TBL] [Abstract][Full Text] [Related]
18. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
[TBL] [Abstract][Full Text] [Related]
19. [Effect of Telbivudine Tablet Combined Jianpi Bushen Recipe on HBV Specific Cytotoxic T Lymphocyte and HBeAg Seroconversion in Patients with HBeAg Positive Chronic Hepatitis B].
Hua Z; Xu W; Fu DC; Li YG; Guo XY; Tu KW; Dai YP
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 May; 36(5):530-4. PubMed ID: 27386641
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B.
Hao C; Wang J; Kang W; Xie Y; Zhou Y; Ma L; Peng M; Bai X; Lian J; Jia Z
Viral Immunol; 2013 Oct; 26(5):336-42. PubMed ID: 24028690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
